OXiGENE Reports Encouraging Safety and Efficacy Data from Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2010 ASCO Annual Meeting
June 06, 2010 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 6, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Publication of Preclinical Data on OXi4503 Demonstrating Potent Anti-Leukemic Effects
May 27, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
OXiGENE Announces Clinical Data to be Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology
May 18, 2010 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 18, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
OXiGENE Reports First Quarter 2010 Financial Results
May 11, 2010 16:17 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
OXiGENE Announces First Quarter 2010 Earnings Conference Call and Webcast
May 05, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and...
OXiGENE Applies for Voluntary Delisting From the Stockholm Exchange
April 23, 2010 02:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 23, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Regains Compliance With NASDAQ Listing Requirements
April 07, 2010 02:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Appoints Tamar D. Howson and Peter J. Langecker to Its Board of Directors
April 05, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 5, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Going Concern Opinion On Its Audited Financial Statements for 2009
March 19, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Change to Board of Directors
March 15, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 15, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...